63687-94-5

Usage

Uses

Used in Pharmaceutical Industry:
11-(4-METHYL-PIPERAZIN-1-YL)-5H-DIBENZO[B,E][1,4]DIAZEPIN-8-OL is used as a potential pharmaceutical agent for its possible therapeutic effects, which are yet to be fully explored. Its unique chemical structure, including the piperazine group with a methyl substituent and the hydroxyl group at the 8th position, suggests that it may have valuable applications in the development of new medications.
Note: Since the provided materials do not specify the exact applications or reasons for the uses of 11-(4-METHYL-PIPERAZIN-1-YL)-5H-DIBENZO[B,E][1,4]DIAZEPIN-8-OL, the above usage is a general statement based on its potential pharmaceutical applications. Further research would be required to identify specific uses and reasons.

Upstream product

• 15980-57-1 8-methoxy-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine 
• 109-01-3 1-methyl-piperazine 
• 93533-11-0 8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 

Relevant academic research and scientific papers

Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: Identification of a novel atypical neuroleptic

The trifluoromethanesulfonyloxy (TfO) analogues 3 and 4 of 8-chloro-11- (4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine, 1) and its 2-chloro isomer (iso-clozapine, 2), respectively, were synthesized via their OMe and OH analogues with the conventional synthetic method of the tricyclic dibenzodiazepines and evaluated pharmacologically along with their parent drugs. The binding profile of the 2-OTf analogue (4) is comparable to the binding profile of 1, although the affinity for the dopamine (DA) D2 receptors is higher (IC50 values are 31 nM and 330 nM for compounds 4 and 1, respectively). Interestingly, no notable affinity for muscarinic receptors could be detected in compound 4. On the contrary, the 8-OTf analogue 3 only displayed affinity for muscarinic M1 receptors (IC50 value 35 nM) and no affinity (IC50 value > 500 nM) for the other receptors tested. The 10 μmol/kg sc dose, but not the 10 μmol/kg po dose, of compound 4 stimulated the output of DA. Increases of 80% and 35% in DOPAC output from the dorsal striatum were seen after sc and po administrations of 10 μmol/kg of compound 4, respectively. Doses up to 100 μmol/kg of compound 3 had no effect on either parameter. Doses up to 100 μmol/kg of compound 4 were not cataleptogenic, but significantly decreased apomorphine-induced locomotor activity. In conclusion, compound 4 (GMC1-169) is a new clozapine-like neuroleptic candidate, which is lacking anticholinergic properties and displays a higher potency, as compared to clozapine (1) itself.